Oxford Asset Management’s Standard BioTools LAB Stock Holding History

Oxford Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-171,659	Closed	-$795K	–	1923
2019 Q3	$795K	Sell	171,659 -138,806	-45%	-$1.09M	0.02%	1058
2019 Q2	$3.83M	Sell	310,465 -14,243	-4%	-$181K	0.08%	352
2019 Q1	$4.32M	Buy	324,708 +61,975	+24%	+$653K	0.09%	239
2018 Q4	$2.27M	Buy	262,733 +228,668	+671%	+$1.78M	0.06%	402
2018 Q3	$257K	Sell	34,065 -5,793	-15%	-$41.2K	0.01%	1538
2018 Q2	$240K	Sell	39,858 -72,534	-65%	-$413K	﹤0.01%	1547
2018 Q1	$656K	Buy	112,392 +81,879	+268%	+$538K	0.01%	1131
2017 Q4	$184K	Buy	+30,513	New	+$167K	﹤0.01%	1466

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Oxford Asset Management's LAB Position: Q4 2019 in Review

Oxford Asset Management sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 171,659 shares — an estimated $795K sold.

Oxford Asset Management first reported a position in LAB in Q4 2017 and held it in 8 quarters. The position peaked at $4.32M in Q1 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

Oxford Asset Management reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 171,659 Standard BioTools shares in Q4 2019, an estimated $795K.
Oxford Asset Management first reported a position in Standard BioTools in Q4 2017 and held it in 8 quarters.
Oxford Asset Management's Standard BioTools position peaked at $4.32M in Q1 2019.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.